Fasching, Peter A <br/><br/>
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  08 2018 
 - 2281-2287 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2017.77.2285  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>BRCA1 Protein--genetics<br/>BRCA2 Protein--genetics<br/>Bevacizumab--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Docetaxel--administration & dosage<br/>Epirubicin--administration & dosage<br/>Female<br/>Genotype<br/>Germ-Line Mutation<br/>Humans<br/>Neoadjuvant Therapy<br/>Receptor, ErbB-2--metabolism<br/>Triple Negative Breast Neoplasms--blood